Zusammenfassung
Die durch Pharmaka bewirkte Erweiterung von Blutgefäßen kann aus verschiedenartigen therapeutischen Gründen erwünscht oder erforderlich sein. Bei der Behandlung der arteriellen Hypertonie ist ein erneutes Interesse an Gefäßerweiternden Substanzen offensichtlich und aus haemodynamischen Gründen durchaus gerechtfertigt. Auch bei der Therapie schwererer Formen der Myokardinsuffizienz haben Vasodilatotoren sich nebst Herzglykosiden und Saluretica einen gewissen Platz erworben, der auch theoretisch gut begründet ist. Enttäuschend sind allerdings die therapeutischen Ergebnisse bei der Anwendung von gefäßerweiternden Pharmaka bei peripheren und zerebralen Durchblutungsstörungen, die auf einem atherosklerotischen Prozeß beruhen. Dagegen kann eine nicht-atherosklerotische Durchblutungsstörung, wobei eine vasospastische Komponente im Spiel ist, wie zum Beispiel beim Syndrom von Raynaud, mitunter günstig auf Vasodilatotoren reagieren.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Amsterdam, E.A., Awan, N.A., De Maris, A.N. and Mason, D.T.: Vasodilators in myocardial infarction: rationale and current status. Drugs 16: 506–521 (1978).
Antonaccio, M.J. and Kerwin, L.: Pre-and postjunctional inhibition of vascular sympathetic function by captopril in SHR. Hypertension 3: (suppl. I), 54–62 (1981).
Awan, N.A., Miller, R.R. and Mason, D.T.: Comparison of effects of nitroprusside and prazosin on left ventricular function and the peripheral circulation in chronic refractory congestive heart failure. Circulation 57: 152–158 (1978).
Barrett, J.D., Eggena, P., Krall, J.F. and Sambhi, M.P.: A comparison of physical characteristics of active renin isolated from aorta, plasma and kidney of the rat. Clin. Science 61: 671–678 (1981).
Brodgen, R.N., Heel, R.C., Speight, T.M. and Avery, G.S.: Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163–197 (1977).
Clough, D.P., Hatton, R. and Matthewman, S.C.: Effect of angiotensin converting enzyme inhibitor on neurogenic vasconstriction in the pithed rat. Br. J. Pharmacol. 73: 296P (1981).
Coffmann, J.D.: Vasodilator drugs in peripheral vascular disease. New Engl. J. Med. 300: 713–716 (1979).
Cushman, D.W., Cheung, H.S., Sabo, E.F. and Ondetti, M.A.: Design of antihypertensive drugs: potent and specific inhibitors of angiotensin converting enzyme. Progr. Cardiovasc. Dis. 21: 176–185 (1978).
Ekelen, W.A.A.J. van and Robles de Medina, E.O.: Coronary arterial spasm and its treatment. Progr.. Pharmacol. 4:43–49 (1981).
Fergusson, R.K. and Vlasses, P.H.: Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril. Am. Heart J. 101: 650–655 (1981).
Fleckenstein, A.: Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol. 17: 149–166 0977).
Gagnon, G., Regoli, D. and Rioux, F.: Studies on the mechanism of action of various vasodilators. Br. J. Pharmacol. 70: 219–227 (1980).
Graham, M. and Pettinger, W.A.: Drug therapy: prazosin. New Engl. J. Med. 300: 232–236 (1979).
Jonge, A. de, Wilffert, B., Kalkman, H.O., Meel, J.C. A. van Thoolen, M.J.M.C, Timmermans, P.B.M.W. M. and Zwieten, P.A. van: Captopril impairs the vascular smooth muscle contraction mediated by postsynaptic α2-adrenoceptors in the pithed rat. Eur. J. Pharmacol. 74: 385–386 (1981).
Jonge, A. de, Wilffert, B., Kalkman, H.O., Thoolen, M.J.M.C, Meel, J.C.A. van, Timmermans, P.B. M.W.M. and Zwieten, P.A. van: Effect of captopril on the regulation of noradrenaline release in the heart and vascular smooth muscle of the pithed rat. Br. J. Pharmacol. 75: 134P (1982).
Kahan, A., Weber, S., Toure, M., Amor, B., Saporta, L., Hodara, M. and Degeorges, M.: Nifedipine in the treatment of Raynaud’s phenomenon. 2nd Joint Meeting of the working groups of the European Society of Cardiology, Pavia 1981.
Kalkman, H.O., Timmermans, P.B.M.W.M. and Zwieten, P.A. van: Characteristics of the antihypertensive properties of ketanserin (R 41 468) in rats. J. Pharmacol, exp. Ther. 222: 227–232 (1982).
Lopez-Sendon, J., Coma-Canella, I., Lombera, F. and Jadraque, L.M.: Use of oral prazosin hydrochloride in congestive failure following acute myocardial infarction. Am. Heart J. 98: 495–505 (1979).
Meel, J.C.A. van, Jonge, A. de, Kalkman, H.O., Wilffert, B., Timmermans, P.B.M.W.M. and Zwieten, P.A. van: Organic and inorganic calcium antagonists reduce vasoconstriction in vivo mediated by postsynaptic α2-adrenoceptors. Naunyn-Schmiedeberg’s Arch. Pharmacol. 316: 288–293 (1981).
Miyazaki, S., Miura, K., Kasai, Y., Abe, K. and Yoshinaga, K.: Relief from digital vasospasn by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud’s phenomenon. Br. Med. J. 284: 310–311 (1982).
Ondetti, M.A., Rubin, B. and Cushman, D.W.: Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196: 441–444 (1977).
Robinson, B.F.: Drugs acting directly on vascular smooth muscle: circulatory actions and secondary effects. Br. J. Clin. Pharmacol. 12: 5S-9S (1981).
Sweet, C.S., Gross, D.M., Arbegast, P.T., Gaul, S.L., Britt, P.M., Ludden, CT., Weitz, D. and Stone, C.A.: Antihypertensive activity of N-((S)-l-(ethoxycarbonyl)-3-phenylpropyl)-L-Ala-L-Pro (MK 421), an orally active converting enzyme inhibitor. J. Pharmacol, exp. Ther. 12: 893–899 (1981).
Taylor, S.H.: Vasodilators and a-adrenoceptor antagonists in hypertension and heart failure. Br. J. Clin. Pharmacol. 12: 27S 2S (1981).
Thuillez, C. Giudicelli, J.F.: Pharmacologie cardiovasculaire des antagonistes du calcium. Thérapie 36: 107–122 (1981).
Unger, T., Kaufmann-Bühler, L., Schölkens, B. and Ganten, D.: Brain converting enzyme inhibition: a possible mechanism for the antihypertensive action of captopril in spontaneously hypertensive rats. Eur. J. Pharmacol. 70: 467–478 (1981).
Vannueten, J.M., Janssen, P.A.J., Beek, J. van, Xhonneux, R., Verbeuren, T.J. and Vanhoutte, P.M.: Vascular effects of ketanserin (R 41 468), a novel antagonist of 5HT2-serotonergic receptors. J. Pharmacol, exp. Ther. 218: 217–230 (1981).
Zwieten, P.A. van: Vasodilator drugs. Progr. Pharmacol. 3: 69–75 (1980).
Zwieten, P.A. van, Meel, J.C.A. van and Timmermans, P.B.M.W.M.: Vascular aspects of calcium antagonists. Pharm. Weekbl. Sci. Ed. 116: 1549–1559 (1981).
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1982 Dr. Dietrich Steinkopff Verlag GmbH & Co. KG, Darmstadt
About this paper
Cite this paper
van Zwieten, P.A., van Meel, J.C.A., de Jonge, A., Kalkman, H.O., Timmermans, P.B.M.W.M. (1982). Zur Pharmakologie vasodilatatorisch wirksamer Pharmaka; neuere Entwicklungen. In: Schaper, W., Gottwik, M.G. (eds) Fortschritte in der Kardiologie. Tagung der Deutschen Gesellschaft für Herz- und Kreislaufforschung, vol 48. Steinkopff. https://doi.org/10.1007/978-3-642-85322-7_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-85322-7_10
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-0609-1
Online ISBN: 978-3-642-85322-7
eBook Packages: Springer Book Archive